These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34632682)

  • 1. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).
    Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Urda L; Amstutz A; Tschumi N; Klimkait T; Labhardt ND
    HIV Med; 2022 Mar; 23(3):287-293. PubMed ID: 34632682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study.
    Devendra A; Kohler M; Letsika M; Khooa H; Motaboli L; Lerotholi M; Tschumi N; Labhardt ND; Brown JA
    AIDS; 2024 Jun; 38(7):1013-1023. PubMed ID: 38381717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
    Asare K; Sookrajh Y; van der Molen J; Khubone T; Lewis L; Lessells RJ; Naidoo K; Sosibo P; van Heerden R; Garrett N; Dorward J
    Lancet Glob Health; 2024 Feb; 12(2):e282-e291. PubMed ID: 38142692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
    Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Glass TR; Amstutz A; Tschumi N; Belus JM; Klimkait T; Labhardt ND
    HIV Med; 2023 Feb; 24(2):153-162. PubMed ID: 35730213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
    Ashta KK; Arora S; Khanna R; Raman N; Anilkumar A; Mohan C
    Curr HIV Res; 2024; 22(1):31-46. PubMed ID: 38284697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.
    Kouamou V; Washaya T; Mapangisana T; Ndhlovu CE; Manasa J
    AIDS; 2024 Apr; 38(5):689-696. PubMed ID: 38227596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir based therapy showed CD4
    Gebremedhin T; Aynalem M; Adem M; Geremew D; Aleka Y; Kiflie A
    Sci Rep; 2024 Feb; 14(1):3297. PubMed ID: 38331983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021.
    Namayanja GA; Da Silva JF; Elur B; Nasirumbi PM; Raizes E; Ssempiira J; Nazziwa E; Nabukenya M; Sewanyana I; Balaba J; Ntale J; Calnan J; Birabwa E; Akao J; Mwangi C; Naluguza M; Ahimbisibwe A; Katureebe C; Nabadda S; Nelson L; Dirlikov E
    PLoS One; 2024; 19(6):e0305129. PubMed ID: 38923981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania.
    Ntamatungiro AJ; Eichenberger A; Okuma J; Vanobberghen F; Ndege R; Kimera N; Francis JM; Kagura J; Weisser M;
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad321. PubMed ID: 37520425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria.
    Abudiore O; Amamilo I; Campbell J; Eigege W; Harwell J; Conroy J; Jiboye J; Lufadeju F; Amole C; Wiwa O; Anweh D; Agbaji OO; Akanmu AS
    PLoS One; 2023; 18(5):e0284767. PubMed ID: 37196012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana.
    Bareng OT; Moyo S; Mudanga M; Sebina K; Koofhethile CK; Choga WT; Moraka NO; Maruapula D; Gobe I; Motswaledi MS; Musonda R; Nkomo B; Ramaabya D; Chebani T; Makuruetsa P; Makhema J; Shapiro R; Lockman S; Gaseitsiwe S
    Viruses; 2024 May; 16(5):. PubMed ID: 38793602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique.
    Ismael N; Gemusse H; Mahumane I; Laurindo O; Magul C; Baxter C; Wilkinson E; Hofstra LM; Wagar N; Bila D; Mabunda N; da Silva J; Oliveira T; Raizes E; Preiser W; Manuel P; Ramos A; Vúbil A
    BMC Infect Dis; 2024 Jul; 24(1):748. PubMed ID: 39075381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi.
    Makonokaya L; Maida A; Kalitera LU; Wang A; Kapanda L; Kayira D; Bottoman M; Nkhoma H; Dunga S; Joaki Z; Chamanga R; Nkanaunena K; Hrapcak S; Nyirenda R; Chiwandira B; Maulidi M; Woelk G; Machekano R; Maphosa T
    AIDS Behav; 2024 Jun; 28(6):2148-2155. PubMed ID: 38615099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
    Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
    Chu C; Tao K; Kouamou V; Avalos A; Scott J; Grant PM; Rhee SY; McCluskey SM; Jordan MR; Morgan RL; Shafer RW
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
    Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
    PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.